Advanced lung cancer has been the leading life-threatening malignant carcinoma worldwide for decades \[[@bb0005]\]. About 85% of advanced lung cancers are non--small cell lung cancer (NSCLC) \[[@bb0010]\], and the efficacy of conventional chemotherapy for this population has reached a ceiling level around 30%-40% \[[@bb0015]\]. Fortunately, the turning point was the discovery of impressive sensitivity of tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients with epidermal growth factor receptor (EGFR) active mutations \[[@bb0020]\]. EGFR targeting therapy has not only doubled the response rate of conventional chemotherapy but also prolonged the overall survival of the advanced NSCLC patients \[[@bb0025]\].

The activating EGFR gene mutants mainly occur in the 18-21 exon which encodes the intracellular tyrosine kinase (TK) domain \[[@bb0030]\]. The classical mutations refer to EGFR exon 19 deletion (E19del) and exon 21 point mutations which take about 85% of all EGFR mutations \[[@bb0035]\]. E19del was the most prevalent approximately 45% of all EGFR mutations and complex for many different mutant positions and patterns \[[@bb0035]\]. The mutant patterns of E19del are mainly deletion, while the point and insertion mutations are not common, respectively \[[@bb0040]\]. About 2.5% E19del would occur in the C-helix part of exon 19 \[[@bb0045]\] which could constructively impact the sensitivity of TKI treatment by activation of TK region \[[@bb0050]\]. However, the C-helix E19del could be undetected by routine genetic mutant testing which often does not cover the whole spectrum of exon 19. So far, the prevalence and effectiveness of EGFR TKIs therapy in this rare population have not been well understood.

To better address the clinical implication of the C-helix E19del in advanced NSCLC patients, we performed a large cohort study by next-generation sequencing (NGS) screening of EGFR mutations and analyzed the characteristics and responsiveness to TKIs in this population. The comparison of clinical characteristics between patients with classical E19del and C-helix E19del mutations was also discussed.

Methods {#s0005}
=======

Patients and Procedures {#s0010}
-----------------------

Eligible patients were required to have pathologically confirmed NSCLC and sufficient tissue for analysis. EGFR mutations were assessed with NGS. Clinical and pathologic data retrospectively collected for analyses included age at diagnosis, gender, smoking status, stage, histology, and EGFR mutant status according to the regular guideline for practice. Twenty-two patients with C-helix E19del received EGFR TKIs treatment and had clinical data available on the outcome. Imaging data were independently reviewed by authors to evaluate their treatment responses according to the Response Evaluation Criteria in Solid Tumors version 1.1 PFS calculated from the date of initiating targeted drugs treatment to radiologic or clinical observation of disease progression. This study was approved by the ethics committee, and a written informed consent was obtained from each participant before the initiation of any study-related procedure.

Targeted NGS {#s0015}
------------

DNA from formalin-fixed, paraffin-embedded tumor tissue and matched blood samples was extracted. Comprehensive genomic profiling was performed by NGS with a 381 cancer-related gene panel covering the whole exons of EGFR gene at a mean coverage depth of \>800×. Genomic DNA sequencing libraries were prepared using the protocols recommended by the Illumina TruSeq DNA Library Preparation Kit. For samples close to the minimum input requirement, additional precapture PCR cycles were performed to generate sufficient PCR product for hybridization. The libraries were hybridized to custom-designed probes (Integrated DNA Technology) including all exons of 170 genes and selected intron of ALK, RET, and ROS1 for the detection of genomic rearrangements. DNA sequencing was performed on a HiSeq3000 sequencing system (Illumina, San Diego, CA) with 2×75-bp paired-end reads. The reads were aligned to the human genome build GRCh37 using BWA (a Burrows-Wheeler aligner). Somatic single nucleotide variant and indel calls were generated using MuTect and GATK, respectively. Somatic copy number alterations were identified with CONTRA. Genomic rearrangements were identified by the software developed in-house analyzing chimeric read pairs.

Statistical Analysis {#s0020}
--------------------

Chi-square test or Fisher's exact test was used to analyze correlations between the patterns of E19del and the characteristic of clinicopathologic factors in advanced NSCLC patients. Statistical analysis was performed using SPSS version 19.0 software (IBM, Armonk, NY). All *P* values were two-sided, and a *P* value of \<.05 was considered statistically significant.

Results {#s0025}
=======

Patients' Characteristics and Treatments {#s0030}
----------------------------------------

From May 2012 to December 2019, a total of 7544 NSCLC patients were screened and 3099 (41.1%) were found to harbor EGFR mutations. Among them, 1438 (46.4%) patients included 97.4% (1400/1438) of the classical E19del and 2.6% (38/1438) of the C-helix E19del; the flowchart of the study design is shown in [Figure 1](#f0005){ref-type="fig"}. The baseline characteristics of the E19del harboring patients have been presented in [Table 1](#t0005){ref-type="table"}, and no statistical difference was observed between patients with classical and C-helix E19del by the median age, gender, smoking status, and histology. A total of 1116 patients with classical E19del and 22 patients with C-helix E19del received EGFR TKIs treatment as first-line therapy, while others received conventional chemotherapy according to local practice. The EGFR TKIs drugs included gefitinib, erlotinib, and icotinib listed in [Table 2](#t0010){ref-type="table"}.Figure 1Flowchart of the study design.Figure 1Table 1Characteristics of NSCLC Patients with *EGFR* Exon19 DeletionTable 1Characteristics*N*No. of Patients (%)*P*ClassicalC-HelixCases1438140038Median age58 (25-91)58 (25-91)57 (36-75).315Years (range)Gender.282Male65363914Female78576124Smoking status.924Prev/curr smoker3503419Never smoker1088105929Histology\<.001Adenocarcinoma1412138032Squamous cell carcinoma990Adenosquamous carcinoma734Sarcomatoid carcinoma752Adenoid cystic carcinoma330Table 2Cases with *EGFR* Exon 19 C-Helix DeletionTable 2IDAmino Acid ChangeGenderAge, YearHistologySmoking StatusTKIBest ResponsePFS (Months)1S752_I759delFemale48AdenocarcinomaNever smokerGefitinib + erlotinibPR12.02S752_I759delFemale64AdenocarcinomaNever smoker\-\--3S752_I759delFemale67AdenocarcinomaNever smoker\-\--4S752_I759delMale52AdenocarcinomaPrev/curr smoker\-\--5S752_I759delFemale67AdenocarcinomaNever smokerIcotinibPR18.06S752_I759delMale70AdenocarcinomaPrev/curr smokerIcotinibSD6.5+7S752_I759delFemale52AdenocarcinomaNever smokerGefitinibPR17.0+8S752_I759delFemale44Adenosquamous carcinomaNever smokerIcotinibPD2.09S752_I759delMale71AdenocarcinomaPrev/curr smokerIcotinibPR54.0+10S752_I759delFemale47AdenocarcinomaNever smokerIcotinibPR8.011S752_I759delFemale67Sarcomatoid carcinomaNever smoker12S752_I759delMale53AdenocarcinomaNever smokerGefitinibSD12.013S752_I759delFemale69AdenocarcinomaNever smokerIcotinibPR34.514S752_I759delMale62AdenocarcinomaPrev/curr smoker15S752_I759delFemale59Adenosquamous carcinomaNever smokerGefitinibSD4.5+16S752_I759delFemale49AdenocarcinomaNever smokerErlotinibPR6.517S752_I759delFemale47Sarcomatoid carcinomaNever smoker18S752_I759delMale63AdenocarcinomaPrev/curr smokerGefitinibPR9.519S752_I759delFemale66AdenocarcinomaNever smokerIcotinibPD2.020A750_E758delMale65AdenocarcinomaPrev/curr smoker\-\--21A750_E758delMale51AdenocarcinomaNever smoker\-\--22A750_E758delFemale64AdenocarcinomaNever smokerGefitinibPR7.023A750_E758delinsPFemale62AdenocarcinomaNever smokerGefitinibPR9.024L747_A755delinsSKGFemale50Adenosquamous carcinomaNever smoker\-\--25E749_K754delMale75AdenocarcinomaNever smoker\-\--26T751_A755delinsNYFemale64AdenocarcinomaNever smokerIcotinibPR7.027T751_E758delFemale49AdenocarcinomaNever smoker\-\--28T751_I759delinsGFemale36AdenocarcinomaNever smokerGefitinibPR18.029T751_I759delinsLDFemale40AdenocarcinomaNever smokerIcotinibPR15.530T751_I759delinsNFemale65AdenocarcinomaNever smokerIcotinibPR22.031T751_I759delFemale58AdenocarcinomaNever smoker\-\--32T751_L760delinsNLMale53Adenosquamous carcinomaNever smokerIcotinibSD5.033T751_D761delinsLYFemale39AdenocarcinomaNever smokerIcotinibPR9.5+34P753_I759delinsGMale60AdenocarcinomaPrev/curr smoker\-\--35A750_E758delinsPFemale46AdenocarcinomaNever smoker\-\--36A750_I759delinsGMale56AdenocarcinomaPrev/curr smoker37A750_E758delMale65AdenocarcinomaPrev/curr smokerGefitinibPR8.0+38A750_E758delMale51AdenocarcinomaNever smoker\-\--

Distribution of C-Helix E19del Screening by NGS {#s0035}
-----------------------------------------------

Of the 38 patients with EGFR exon 19 C-helix deletion, 50.0% (19/38) of locus occurred on S752; 21.1% (8/38) of locus occurred on A750 and T751; and 2.6% (1/38) occurred on L747, E749, and P753 ([Table 2](#t0010){ref-type="table"}, [Figure 2](#f0010){ref-type="fig"}*A*). The locus of classical E19del was mainly distributed from E746 to P747 and C-helix E19del was distributed from P747 to P753 ([Figure 2](#f0010){ref-type="fig"}*B*). Furthermore, TP53 mutant (55.3%, 21/38) was the most frequent coexisting genetic alteration in all patients with EGFR exon 19 C-helix deletion ([Figure 2](#f0010){ref-type="fig"}*C*).Figure 2*EGFR* exon 19 c-helix deletion mutation distribution. (A) Distribution of *EGFR* exon 19 c-helix patients categorized according to locus. (B) Comparison of classical and c-helix loci from E746 to P753. (C) Heatmap showed the next-generation sequencing results for co-mutation spectrum of *EGFR* exon 19 c-helix deletion mutations in all patients.Figure 2

Clinical Outcome of EGFR Exon 19 C-Helix Deletion Patients {#s0040}
----------------------------------------------------------

After median follow-up duration of 94.0 months, all 22 patients with C-helix E19del as p.S752_I759del, p.A750_E758del, p.A750_E758delinsP, p.T751_A755delinsNY, p.T751_I759delinsG, p.T751_I759delinsLD, p.T751_I759delinsN, p.T751_L760delinsNL, and p.T751_D761delinsLY reached the best response as partial response (PR) rate (72.7%), and the progression-free survival (PFS) was 12.0 months. The response rate to TKIs as first-line palliative therapy in patients with C-helix E19del in our study ([Table 2](#t0010){ref-type="table"}). Kaplan-Meier survival curves showed no statistical significance of PFS after EGFR TKIs between classical (*n*=1400) and c-helix (*n*=38) with E19del patients (8.5 months vs 12.0 months, *P* = .06) ([Figure 3](#f0015){ref-type="fig"}).Figure 3Comparison of classical and c-helix with EGFR-TKIs therapy (8.5 months vs 12.0 months, *P* = .06)Figure 3

Discussion {#s0045}
==========

Activating EGFR gene mutations are the well-known driver mutations in advanced NSCLC, occurring in 10%-15% and 50%-60% in white and Asian populations, respectively \[[@bb0055],[@bb0060]\]. Mutations within exons 18, 19, and 21 are associated with the sensitivity to EGFR TKIs such as gefitinib, erlotinib, afatinib, and icotinib \[[@bb0065]\]; E19del are in-frame deletions and are found in about 48% of EGFR mutant lung cancers \[[@bb0070]\]. More than 50 patterns of E19del mutations have been reported, and p.E746_A750 is the most common deletion accounting for over 45% in all \[[@bb0075]\]. E19del mutations occur in a protein strand (called the β3 strand) adjacent to the C-helix which is within the N-lobe of EGFR TK domain \[[@bb0080]\]. It is postulated that reducing the length of this strand may also favor the activation of EGFR TK region \[[@bb0050]\]. However, the characteristics and responsiveness of EGFR TKIs in NSCLC patients with C-helix E19del are unclear partly because they are not hotspots and could be missed by the regular gene mutation testing, such as ARMS and direct sequencing \[[@bb0085]\].

In this study, we used massive parallel NGS platform to screen EGFR mutations and preliminarily found that about 2.4% of E19del occurred in the C-helix part consistent with result from previous study \[[@bb0045]\], and most of them combined with insertions at the same time. No significant different clinical characteristic of patients with C-helix E19del could be found compared with those that carried classical E19del, except for histology. All 22 patients with C-helix E19del as p.S752_I759del, p.A750_E758del, p.A750_E758delinsP, p.T751_A755delinsNY, p.T751_I759delinsG, p.T751_I759delinsLD, p.T751_I759delinsN, p.T751_L760delinsNL, and p.T751_D761delinsLY reached the best response as PR rate (72.7%), and the PFS was 12.0 months. As far as we know, the responsiveness to TKIs in EGFR p.T751_I759delinsG has never been reported before.

Schrock et al. \[[@bb0090]\] reported that 3.5% (14/390) of E19del in C-helix were within the 753-761 amino acid (AA) range and 96.5% (286/390) were classical E19del within the 743-754 AA range by genomic comprehensive profiling in previous EGFR-negative patients. The majority of C-helix E19del were within 752-759 AA \[[@bb0090]\]. We reported that the prevalence of C-helix E19del was 2.6% from large cohort, which is close to the result from this study. One patient with p.T751_I759delinsN received TKI treatment and achieved PR consistent according to their study, and the response was consistent with ours. In our study, p.S752_I759del, p.A750_E758del, p.A750_E758delinsP, p.T751_A755delinsNY, p.T751_I759delinsG, p.T751_I759delinsLD, p.T751_I759delinsN, p.T751_L760delinsNL, and p.T751_D761delinsLY have been proved to be sensitizing EGFR mutations in advanced NSCLC by longer than 1-year PFS after TKIs treatment. The unknown EGFR p.T751_I759delinsG was affected at the same position in C-helix like p.T751_I759delinsN but with different insertion of AA which could presumably be oncogenic either. However, p.T751_I759delinsS seemed to have intrinsic resistance to gefitinib, and PFS was only 2.0 months in another study \[[@bb0095]\]. In that case, we presumed that both of the deletion position and the insertion AA may influence the sensitivity of EGFR TKIs. Notably, those 22 patients would have no chance to accept TKIs therapy if the EGFR mutation was not detected by NGS platform. NGS has shown to have superior advantages in screening for uncommon EGFR mutations that allow detection of multiple genes and relevant mutant patterns simultaneously from tumor specimens \[[@bb0100]\]. There was no concurrent of well-known driver gene alterations in patients with C-helix E19del, such as ALK/RET/ROS1 rearrangement and KRAS mutation. It may reflect the pro-oncogenic nature of C-helix E19del in NSCLC patients similar to the mutual exclusiveness of classical EGFR mutations with other driver gene alterations \[[@bb0105]\]. Of note, most of the patients (35/38, 92.1%) carried concurrent gene alterations, and 55.3% (21/38) of them carried TP53 mutations. The mutation rate of TP53 was 56.1% in one study of 1441 metastatic NSCLC patients \[[@bb0110]\]. In their study, the TP53 mutation correlated with a negative prognosis regardless of EGFR mutation status. Furthermore, about half of TP53 mutations (11/21) have been detected in patients with S752_I749del, which has never been reported before. Another tumor suppressor gene NF1 mutation has also been detected in five patients, and four of them carried concomitant TP53 mutations. NF1 mutations have been reported to occur more often with oncogenic alterations and TP53 mutations \[[@bb0115]\], but the clinical significance is unknown.

The main limitation of our research was that we retrospectively collected data and some bias in our conclusion could not be avoided. Although all 22 patients with C-helix deletion showed good response to TKIs and their disease was well controlled, we could not confirm the predictive value of C-helix deletion since the outcome of those who harbored the same deletion but accepted chemotherapy was unknown. Longer follow-up and further structural and functional research for those uncommon deletions should be conducted in future to verify our findings.

In summary, our study increases the evidence supporting EGFR TKIs treatment as first-line therapy for advanced NSCLC patients with C-helix E19del. Reliable detection of drug-sensitive EGFR mutations is crucial in the care of advanced NSCLC patients. NGS platform should be more suitable for screening those uncommon mutants than regular testing, especially in those patients who are reluctant to receive chemotherapy.
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